

Amendments to the Claims

Please cancel claims 5-17 without prejudice. Please amend claims 1-4 as follows:

Claim 1 (currently amended): A recombinant LK6 protein comprising polypeptide consisting of amino acid sequences sequence of human apolipoprotein(a) kringle domains IV36 SEQ ID NO:4, and having anti-angiogenic activity.

Claim 2 (currently amended): A recombinant LK7 protein comprising polypeptide consisting of amino acid sequences sequence of human apolipoprotein(a) kringle domains IV37 SEQ ID NO:6, and having anti-angiogenic activity.

Claim 3 (currently amended): A recombinant LK8 protein comprising polypeptide consisting of amino acid sequences sequence of human apolipoprotein(a) kringle domains V38 SEQ ID NO:8, and having anti-angiogenic activity.

Claim 4 (currently amended): A recombinant LK68 protein comprising polypeptide consisting of amino acid sequences sequence of human apolipoprotein(a) kringle domains IV36, IV37 and V38 in a serial manner SEQ ID NO:2, and having anti-angiogenic activity.

Claim 5 (canceled)

Claim 6 (canceled)

Serial No. 10/088,548

PATENT
Client/Matter No.: 58049-00002

Claim 7 (canceled)

Claim 8 (canceled)

Claim 9 (canceled)

Claim 10 (canceled)

Claim 11 (canceled)

Claim 12 (canceled)

Claim 13 (canceled)

Claim 14 (canceled)

Claim 15 (canceled)

Claim 16 (canceled)

Claim 17 (canceled)

Claim 18 (withdrawn; currently amended): A method for treating angiogenesis-mediated disease which comprises administering therapeutically effective amount of LK68 ~~protein, polypeptide its single kringles, or their functional equivalents~~ to a human or animal.

Claim 19 (withdrawn): The method for treating angiogenesis-mediated disease of claim 18, wherein the angiogenesis-mediated disease is cancer, rheumatoid arthritis, psoriasis, or ocular angiogenic disease.

Please add the following new claims 20-33 as follows:

Claim 20 (new): A composition comprising the polypeptide according to claim 1, and a pharmaceutically acceptable carrier thereof.

Claim 21 (new): A composition comprising the polypeptide according to claim 2, and a pharmaceutically acceptable carrier thereof.

Claim 22 (new): A composition comprising the polypeptide according to claim 3, and a pharmaceutically acceptable carrier thereof.

Claim 23 (new): A composition comprising the polypeptide according to claim 4, and a pharmaceutically acceptable carrier thereof.

Claim 24 (new): A method for inhibiting endothelial cell migration comprising contacting a population of endothelial cells with the polypeptide according to claim 1.

Claim 25 (new): A method for inhibiting endothelial cell migration comprising contacting a population of endothelial cells with the polypeptide according to claim 2.

Claim 26 (new): A method for inhibiting endothelial cell migration comprising contacting a population of endothelial cells with the polypeptide according to claim 3.

Claim 27 (new): A method for inhibiting endothelial cell migration comprising contacting a population of endothelial cells with the polypeptide according to claim 4.

Claim 28 (new): A method of reducing tumor growth comprising contacting the tumor with the polypeptide according to claim 1.

Claim 29 (new): A method of reducing tumor growth comprising contacting the tumor with the polypeptide according to claim 2.

Claim 30 (new): A method of reducing tumor growth comprising contacting the tumor with the polypeptide according to claim 3.

Claim 31 (new): A method of reducing tumor growth comprising contacting the tumor with the polypeptide according to claim 4.

Claim 32 (new): A method for inhibiting endothelial cell proliferation comprising contacting a population of endothelial cells with the polypeptide according to claim 4.

Claim 33 (new): A method of inhibiting growth of capillaries comprising contacting the polypeptide according to claim 4 with a region of capillary formation.